Moderna price to sales ratio MRNA

Market value divided by revenue over the last twelve months, since 2019.

Today, Oct 23, 2026: 35.9×
8-year median: 5.6×
Against its 8-year history: 78th; percentile: 0 is its lowest day, 100 its highest
8-year range: 2.0× to 198×
Peer median: 6.8×

Moderna's price to sales ratio is 35.9× as of Oct 23, 2026.

That is above its 8-year median of 5.6×, higher than on 78% of days in the last 8 years.

Over that time it ranged from 2.0× in Sep 2022 to 198× in Dec 2020.

The median for 10 biotech stocks of a similar size is 6.8×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	35.9×	5.4×	40.3×
2025	5.5×	2.5×	5.9×
2024	3.0×	2.8×	12.4×
2023	4.2×	2.5×	4.2×
2022	3.2×	2.0×	7.3×
2021	8.7×	7.9×	181×
2020	168×	74.5×	198×
2019	79.7×	34.3×	84.5×

Against its peers

Companies in Biotechnology nearest Moderna's size, closest first, today.

Company	Price to sales ratio
MRNAModerna	35.9×
REGNRegeneron Pharmaceuticals	5.3×
VRTXVertex Pharmaceuticals	10.6×
ONCBeOne Medicines	7.0×
ALNYAlnylam Pharmaceuticals	6.2×
UTHRUnited Therapeutics	8.0×
INCYIncyte	4.0×
EXELExelixis	6.6×
NBIXNeurocrine Biosciences	4.3×
HALOHalozyme Therapeutics	8.6×
TECHBIO-TECHNE	9.4×
Peer median	6.8×

Where Moderna ranks

#57of 63Biotech stocks with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Moderna

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.